Stay updated on Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial
Sign up to get notified when there's something new on the Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial page.

Latest updates to the Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial page
- Check2 days agoChange DetectedThe page now shows a new revision tag: v3.6.6, replacing the previous v3.6.5, indicating a backend/document revision without altering the displayed study details.SummaryDifference0.0%

- Check9 days agoChange Detected2016 ( U.S. NIH Grant/Contract ) was added to the study's identifiers. This indicates NIH funding associated with the trial, but it does not alter the study content or user actions.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedA new revision entry v3.6.5 was added and the previous revision v3.6.4 was removed from the revision records, updating the page's version history.SummaryDifference0.0%

- Check31 days agoChange DetectedThe list of study locations now shows 108 sites across multiple countries, expanding from the prior 44 locations.SummaryDifference5%

- Check38 days agoChange DetectedThe page's revision label was updated from v3.6.3 to v3.6.4, indicating an administrative update to the page metadata. There is no change to the study content or information presented to users.SummaryDifference0.0%

- Check60 days agoChange DetectedRevision label updated from v3.6.2 to v3.6.3, indicating a minor administrative update to the page. The underlying content of the study entry remains unchanged.SummaryDifference0.0%

Stay in the know with updates to Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial page.